Evidence map›Paper›PMID 38698706›Full record

ArticleThoracic cancer2024

Concomitant osimertinib and antituberculosis therapy in an elderly patient with EGFR-mutated lung cancer and pulmonary tuberculosis: A case report.

Hiroaki Matsuura, Hisao Higo, Tadahiro Kuribayashi, Akihiko Tamaoki, Takamasa Nakasuka, Mari Uno, Go Makimoto, Kiichiro Ninomiya, Masanori Fujii, Kammei Rai and 7 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Thoracic cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Hiroaki MatsuuraDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Hisao HigoDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Tadahiro KuribayashiDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Akihiko TamaokiOkayama Health Foundation Hospital, Okayama Health Foundation, Okayama, Japan.
Takamasa NakasukaDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Mari UnoDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Go MakimotoDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Kiichiro NinomiyaDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Masanori FujiiDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Kammei RaiDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Eiki IchiharaDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Katsuyuki HottaDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.ORCID 0000-0002-0112-0843
Nobuaki MiyaharaDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Masahiro TabataDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Yoshinobu MaedaDepartment of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Katsuyuki KiuraDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.
Kadoaki OhashiDepartment of Respiratory Medicine, Okayama University Hospital, Okayama, Japan.ORCID 0000-0002-5180-3933

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The concurrent incidence of lung cancer and tuberculosis is expected to escalate due to the projected growth in the older population. Combination therapy with osimertinib and antituberculosis drugs has not been well-established. We report a case of successful treatment involving the concomitant administration of osimertinib and antituberculosis drugs in an older patient, an 89-year-old female, diagnosed with epidermal growth factor receptor (EGFR)-mutant lung cancer and pulmonary tuberculosis. Accumulating evidence is warranted to develop an optimal treatment strategy for patients with lung cancer and tuberculosis.

Indexed as

AcrylamidesAniline CompoundsAntitubercular AgentsErbB ReceptorsLung NeoplasmsMutationTuberculosis, PulmonaryAged, 80 and overFemaleHumansIndolesPyrimidinesAcrylamidesAniline CompoundsAntitubercular AgentsEGFR protein, humanErbB ReceptorsIndolesosimertinibPyrimidinescase reportEGFR‐mutated lung cancerosimertinibpulmonary tuberculosisrifampicin

Identifiers

PMID38698706
PMCPMC11168902

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.